Category: Reformulary Group

CIX CANADIAN INNOVATION EXCHANGE ANNOUNCED REFORMULARY GROUP AS A CIX TOP 20 EARLY INNOVATIVE CANADIAN TECHNOLOGY START-UPS OF 2019

Toronto, Canada, Wednesday, September 4, 2019 – Today, CIX Canadian Innovation Exchange announced the CIX TOP 20 Early and CIX TOP 10 Growth innovative Canadian technology startups that have been inducted into the annual program. The selected companies represent a diverse range of tech including software, AI, medtech, fintech, big data, aerospace, security, Saas and cleantech. These game-changing, on-the-rise …

Continue reading

CANADA’S FIRST EVIDENCE-BASED MEDICAL CANNABIS FORMULARY LAUNCHES TODAY

TORONTO, March 20, 2019 (GLOBE NEWSWIRE) — Reformulary Group, a Canadian healthcare technology company, today announced the launch of Cannabis Standard™ – the first evidence-based medical cannabis formulary and research platform for patients, employers and physicians – available on a subscription basis to patients. Cannabis Standard, one-part formulary and one-part research platform, uses evidence to help …

Continue reading

REFORMULARY GROUP SIGNS APHRIA TO PROVIDE MEDICAL CANNABIS FOR EMPLOYER PLANS

TORONTO, May 29, 2018 (GLOBE NEWSWIRE) — Reformulary Group, Canada’s leading, independent drug plan management company, today announced it has signed Leamington, Ontario-based cannabis producer Aphria Inc. as its second Licensed Producer of medical cannabis for employer plans. MORE>>

REFORMULARY GROUP SIGNS MEDRELEAF AS FIRST LICENSED PRODUCER FOR NEW MEDICAL CANNABIS FORMULARY

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) — Reformulary Group, Canada’s leading, independent drug plan management company, today announced it has signed MedReleaf as its first Licensed Producer of medical cannabis. The agreement will provide subscribers of Reformulary’s Cannabis Standard – the first cannabis formulary in Canada – with preferred pricing options and will support the development of …

Continue reading

EXPERT GROUP TO REVIEW EVIDENCE FOR USE OF MEDICAL CANNABIS FOR EMPLOYER PLANS

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) — Today, Reformulary Group, Canada’s leading, independent drug plan management company, announced its Cannabis Formulary Committee, which will review the best available evidence for medical cannabis and provide expert opinions and criteria for its use in specific indications. The Cannabis Formulary Committee will recommend specific medical uses and develop …

Continue reading